Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 Combinations vs Monotherapy in Advanced KRAS G12D Mutated Pancreatic Cancer
NCT07784374Phase 2Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GFH375 in pancreatic cancer (PC), sponsored by GenFleet Therapeutics. Primary endpoints: Progression-Free Survival and Body Weight. Started Aug 2026; status: recruiting.
02
Drugs
GFH375
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07784374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784374.